Agios Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AGIO)

$77.70 -1.09 (-1.38 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$78.79
Today's Range$76.88 - $79.13
52-Week Range$45.11 - $82.96
VolumeN/A
Average Volume846,172 shs
Market Capitalization$3.79 billion
P/E Ratio-11.53
Dividend YieldN/A
Beta2.12

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AGIO
CUSIPN/A
Phone+1-617-6498600

Debt

Debt-to-Equity RatioN/A
Current Ratio4.69%
Quick Ratio4.69%

Price-To-Earnings

Trailing P/E Ratio-11.5281899109792
Forward P/E Ratio-12.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$43.01 million
Price / Sales103.57
Cash FlowN/A
Price / CashN/A
Book Value$6.74 per share
Price / Book11.53

Profitability

Trailing EPS($6.74)
Net Income$-314,670,000.00
Net Margins-731.60%
Return on Equity-76.67%
Return on Assets-48.05%

Miscellaneous

Employees382
Outstanding Shares57,330,000

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) issued its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.65) by $0.16. The biopharmaceutical company earned $9.80 million during the quarter, compared to analyst estimates of $12.65 million. Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The firm's revenue was down 56.7% compared to the same quarter last year. During the same period last year, the business earned ($1.34) EPS. View Agios Pharmaceuticals' Earnings History.

When will Agios Pharmaceuticals make its next earnings announcement?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Agios Pharmaceuticals.

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2018?

10 equities research analysts have issued 12-month price targets for Agios Pharmaceuticals' shares. Their predictions range from $75.00 to $101.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $85.67 in the next year. View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for  AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company." (1/16/2018)
  • 2. Cann analysts commented, "Agios announced on December 5, 2017 the appointment of Jacqualyn Fouse, Ph.D. to its board of directors. Dr. Fouse has served as executive chair of Dermavant since July 2017 and was previously chief operating officer of Celgene and member of Celgene’s board of directors." (12/5/2017)

Who are some of Agios Pharmaceuticals' key competitors?

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

  • David P. Schenkein M.D., President, Chief Executive Officer, Director (Age 59)
  • Andrew Hirsch, Chief Financial Officer (Age 46)
  • Scott Biller Ph.D., Chief Scientific Officer (Age 61)
  • Christopher Bowden M.D., Chief Medical Officer (Age 56)
  • Steven L. Hoerter, Chief Commercial Officer (Age 46)
  • Jacqualyn A. Fouse Ph.D., Director (Age 56)
  • David Scadden M.D., Director
  • Paul J. Clancy, Independent Director (Age 55)
  • Ian T. Clark, Independent Director (Age 56)
  • Kaye I. Foster-Cheek, Independent Director (Age 57)

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include CELGENE EUROPEAN INVESTMENT COMPANY LLC (12.10%), BlackRock Inc. (5.05%), First Trust Advisors LP (1.46%), Alkeon Capital Management LLC (0.89%), Geode Capital Management LLC (0.66%) and UBS Asset Management Americas Inc. (0.62%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Celgene European Investment Co, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Quantitative Investment Management LLC, BlackRock Inc., Spark Investment Management LLC, Wells Fargo & Company MN, Lazard Asset Management LLC, Alliancebernstein L.P., Guggenheim Capital LLC and Belpointe Asset Management LLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., First Trust Advisors LP, OppenheimerFunds Inc., Two Sigma Advisers LP, Alkeon Capital Management LLC, California Public Employees Retirement System, Eaton Vance Management and Wealthstreet Investment Advisors LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Celgene European Investment Co and Corp /De/ Celgene. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $77.70.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $4.45 billion and generates $43.01 million in revenue each year. The biopharmaceutical company earns $-314,670,000.00 in net income (profit) each year or ($6.74) on an earnings per share basis. Agios Pharmaceuticals employs 382 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (AGIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  245 (Vote Underperform)
Total Votes:  498
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Agios Pharmaceuticals (NASDAQ:AGIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.912.922.90
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $85.67$77.00$75.70$74.75
Price Target Upside: 9.87% upside9.48% upside26.93% upside23.43% upside

Agios Pharmaceuticals (NASDAQ:AGIO) Consensus Price Target History

Price Target History for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018SunTrust BanksReiterated RatingBuy -> Buy$80.00 -> $101.00LowView Rating Details
2/15/2018JPMorgan Chase & Co.Boost Price TargetOverweight -> Overweight$76.00 -> $85.00LowView Rating Details
2/15/2018Credit Suisse GroupBoost Price TargetOutperform -> Outperform$66.00 -> $80.00LowView Rating Details
2/15/2018Needham & Company LLCBoost Price TargetBuy -> Buy$72.00 -> $86.00LowView Rating Details
2/14/2018OppenheimerDowngradeOutperform -> Market PerformLowView Rating Details
1/18/2018Royal Bank of CanadaBoost Price TargetOutperform$91.00MediumView Rating Details
12/12/2017Canaccord GenuitySet Price TargetBuy$90.00HighView Rating Details
12/5/2017CannReiterated RatingBuyMediumView Rating Details
8/2/2017Leerink SwannUpgradeMarket Perform -> Outperform$50.00 -> $80.00HighView Rating Details
8/1/2017Janney Montgomery ScottReiterated RatingHoldHighView Rating Details
2/16/2017CowenReiterated RatingBuyN/AView Rating Details
1/17/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralN/AView Rating Details
8/10/2016Goldman Sachs GroupReiterated RatingNeutral$46.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings History and Estimates Chart

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ AGIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($1.68)N/AView Earnings Details
2/14/2018Q4 2017($1.65)($1.81)$12.65 million$9.80 millionViewListenView Earnings Details
11/1/2017Q3 2017($1.78)($1.59)$10.85 million$11.35 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.57)($1.78)$10.68 million$11.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.80)($1.56)$9.65 million$10.51 millionViewListenView Earnings Details
2/16/2017Q416($1.51)($1.34)$10.89 million$22.65 millionViewListenView Earnings Details
11/3/2016Q316($1.52)($1.63)$7.82 million$8.98 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.27)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.86)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.55)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 million$33.90 millionViewListenView Earnings Details
8/7/2014Q2($0.47)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.37)($0.39)$7.19 million$8.41 millionViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)$6.22 million$6.27 millionViewListenView Earnings Details
9/5/2013Q2 2013($0.28)($2.80)$6.19 million$6.27 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings Estimates

2018 EPS Consensus Estimate: ($5.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.65)($1.57)($1.61)
Q2 20183($1.63)($1.44)($1.55)
Q3 20183($1.89)($1.42)($1.66)
Q4 20183($1.53)($0.58)($1.15)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.43%
Institutional Ownership Percentage: 84.04%
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/5/2018Scott BillerInsiderSell3,000$76.04$228,120.00View SEC Filing  
2/1/2018Christopher BowdenInsiderSell2,000$78.75$157,500.002,881View SEC Filing  
2/1/2018David P SchenkeinCEOSell13,000$78.75$1,023,750.0013,000View SEC Filing  
1/26/2018David P SchenkeinCEOSell23,572$81.09$1,911,453.4823,572View SEC Filing  
1/24/2018David P SchenkeinCEOSell46,408$80.01$3,713,104.0832,875View SEC Filing  
1/23/2018Corp /De/ CelgeneMajor ShareholderBuy851,154$67.00$57,027,318.001,374,599View SEC Filing  
1/23/2018Steven L HoerterInsiderSell25,000$74.83$1,870,750.0025,000View SEC Filing  
1/16/2018David P SchenkeinCEOSell53,000$73.16$3,877,480.0053,000View SEC Filing  
1/12/2018Carman AlensonInsiderSell2,150$75.00$161,250.002,150View SEC Filing  
1/10/2018Scott BillerInsiderSell3,000$65.00$195,000.0056,059View SEC Filing  
12/7/2017Lewis Clayton Jr. CantleyDirectorSell3,838$59.37$227,862.0680,851View SEC Filing  
12/1/2017David P SchenkeinCEOSell6,000$61.55$369,300.006,000View SEC Filing  
12/1/2017Scott BillerInsiderSell2,146$60.79$130,455.348,410View SEC Filing  
11/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$60.88$243,520.0082,394View SEC Filing  
11/1/2017David P SchenkeinCEOSell6,000$63.85$383,100.00View SEC Filing  
11/1/2017Scott BillerInsiderSell2,146$62.69$134,532.74View SEC Filing  
10/17/2017Lewis Clayton Jr. CantleyDirectorSell4,000$71.10$284,400.0084,394View SEC Filing  
10/16/2017Lewis Clayton Jr. CantleyDirectorSell1,000$71.09$71,090.0084,394View SEC Filing  
10/4/2017David P SchenkeinCEOSell80,000$70.14$5,611,200.00View SEC Filing  
10/4/2017Scott BillerInsiderSell10,470$70.00$732,900.00View SEC Filing  
10/2/2017David P SchenkeinCEOSell6,000$66.76$400,560.00View SEC Filing  
10/2/2017Scott BillerInsiderSell2,146$67.23$144,275.58View SEC Filing  
9/18/2017David P SchenkeinCEOSell35,000$67.12$2,349,200.0035,000View SEC Filing  
9/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$65.59$262,360.0086,394View SEC Filing  
9/13/2017Lewis Clayton Jr. CantleyDirectorSell1,000$65.47$65,470.0086,394View SEC Filing  
9/11/2017Scott BillerInsiderSell15,000$65.00$975,000.006,264View SEC Filing  
9/1/2017David P SchenkeinCEOSell6,000$62.20$373,200.006,000View SEC Filing  
9/1/2017Scott BillerInsiderSell2,146$61.99$133,030.548,410View SEC Filing  
8/23/2017Lewis Clayton Jr. CantleyDirectorSell4,000$56.85$227,400.00View SEC Filing  
8/2/2017David P SchenkeinCEOSell27,000$59.95$1,618,650.003,000View SEC Filing  
8/2/2017Scott BillerInsiderSell23,146$59.60$1,379,501.608,410View SEC Filing  
7/20/2017Lewis Clayton Jr. CantleyDirectorSell9,000$56.36$507,240.0086,697View SEC Filing  
7/19/2017Lewis Clayton Jr. CantleyDirectorSell3,500$56.14$196,490.0086,697View SEC Filing  
7/7/2017Scott BillerInsiderSell2,146$55.00$118,030.008,410View SEC Filing  
7/3/2017David P SchenkeinCEOSell3,000$51.18$153,540.003,000View SEC Filing  
6/21/2017Scott BillerInsiderSell4,292$55.00$236,060.00View SEC Filing  
6/14/2017Lewis Clayton Jr. CantleyDirectorSell2,000$50.87$101,740.0090,197View SEC Filing  
6/7/2017David P SchenkeinCEOSell3,000$50.02$150,060.001,100View SEC Filing  
5/25/2017Lewis Clayton Jr. CantleyDirectorSell2,036$47.10$95,895.6091,206View SEC Filing  
5/1/2017David P SchenkeinCEOSell3,000$50.06$150,180.003,000View SEC Filing  
4/24/2017Celgene European Investment CoMajor ShareholderBuy624,575$49.50$30,916,462.50View SEC Filing  
4/18/2017Lewis Clayton Jr. CantleyDirectorSell5,090$54.37$276,743.3093,751View SEC Filing  
4/17/2017Lewis Clayton Jr. CantleyDirectorSell2,036$55.24$112,468.6493,751View SEC Filing  
4/3/2017David P SchenkeinCEOSell3,000$58.62$175,860.003,000View SEC Filing  
4/3/2017Scott BillerInsiderSell2,146$58.03$124,532.38View SEC Filing  
3/23/2017Lewis Clayton Jr. CantleyDirectorSell2,036$53.11$108,131.9694,769View SEC Filing  
3/20/2017Scott BillerInsiderSell6,438$55.00$354,090.0021,403View SEC Filing  
3/6/2017Robert NelsenDirectorSell40,599$50.84$2,064,053.16109,230View SEC Filing  
2/28/2017Robert NelsenDirectorSell243,082$49.36$11,998,527.52109,230View SEC Filing  
2/23/2017Robert NelsenDirectorSell135,364$49.37$6,682,920.6873,078View SEC Filing  
2/16/2017David P SchenkeinCEOSell6,000$50.01$300,060.006,000View SEC Filing  
10/27/2016Lewis Clayton Jr. CantleyDirectorSell2,504$48.94$122,545.76108,405View SEC Filing  
10/5/2016Scott BillerInsiderSell5,000$55.00$275,000.0048,270View SEC Filing  
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00109,659View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05109,659View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.0048,270View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87110,913View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87110,913View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20112,167View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95112,167View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52125,921View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99125,921View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.0081,376View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76127,175View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76128,429View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00128,429View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76129,683View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60131,086View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72131,713View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52132,967View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.0061,835View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64138,299View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.0081,835View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.0034,070View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64143,002View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.0081,835View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.0034,070View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00147,854View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00141,835View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00131,835View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00200,090View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00205,090View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.0030,000View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.0046,583View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00209,090View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00209,090View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.0030,000View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86109,090View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00109,090View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Agios Pharmaceuticals (NASDAQ AGIO) News Headlines

Source:
DateHeadline
Agios Pharmaceuticals Inc (AGIO) Forecasted to Earn Q3 2018 Earnings of ($1.67) Per ShareAgios Pharmaceuticals Inc (AGIO) Forecasted to Earn Q3 2018 Earnings of ($1.67) Per Share
www.americanbankingnews.com - February 19 at 4:30 AM
Oppenheimer Equities Analysts Lift Earnings Estimates for Agios Pharmaceuticals Inc (AGIO)Oppenheimer Equities Analysts Lift Earnings Estimates for Agios Pharmaceuticals Inc (AGIO)
www.americanbankingnews.com - February 19 at 3:16 AM
Leerink Swann Weighs in on Agios Pharmaceuticals Incs Q1 2018 Earnings (AGIO)Leerink Swann Weighs in on Agios Pharmaceuticals Inc's Q1 2018 Earnings (AGIO)
www.americanbankingnews.com - February 19 at 3:16 AM
FDA Grants Agios (AGIO) Leukemia Candidate Priority ReviewFDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
finance.yahoo.com - February 16 at 5:19 PM
Analysts Set Expectations for Agios Pharmaceuticals Incs FY2022 Earnings (AGIO)Analysts Set Expectations for Agios Pharmaceuticals Inc's FY2022 Earnings (AGIO)
www.americanbankingnews.com - February 16 at 4:32 PM
Agios Pharmaceuticals Inc Forecasted to Post Q1 2018 Earnings of ($1.65) Per Share (AGIO)Agios Pharmaceuticals Inc Forecasted to Post Q1 2018 Earnings of ($1.65) Per Share (AGIO)
www.americanbankingnews.com - February 16 at 8:26 AM
Needham & Company LLC Reiterates Buy Rating for Agios Pharmaceuticals (AGIO)Needham & Company LLC Reiterates Buy Rating for Agios Pharmaceuticals (AGIO)
www.americanbankingnews.com - February 15 at 9:10 PM
Agios Pharma (AGIO) Says FDA Accepted NDA and Granted Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 MutationAgios Pharma (AGIO) Says FDA Accepted NDA and Granted Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
www.streetinsider.com - February 15 at 5:22 PM
FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 MutationFDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
finance.yahoo.com - February 15 at 5:22 PM
JPMorgan Chase & Co. Increases Agios Pharmaceuticals (AGIO) Price Target to $85.00JPMorgan Chase & Co. Increases Agios Pharmaceuticals (AGIO) Price Target to $85.00
www.americanbankingnews.com - February 15 at 3:24 PM
Agios Pharmaceuticals (AGIO) PT Raised to $101.00 at SunTrust BanksAgios Pharmaceuticals (AGIO) PT Raised to $101.00 at SunTrust Banks
www.americanbankingnews.com - February 15 at 12:32 PM
Credit Suisse Group Reiterates "Outperform" Rating for Agios Pharmaceuticals (AGIO)Credit Suisse Group Reiterates "Outperform" Rating for Agios Pharmaceuticals (AGIO)
www.americanbankingnews.com - February 15 at 11:18 AM
Agios Pharmaceuticals (AGIO) Stock Rating Lowered by OppenheimerAgios Pharmaceuticals (AGIO) Stock Rating Lowered by Oppenheimer
www.americanbankingnews.com - February 14 at 11:42 PM
UBS Group Downgrades Agios Pharmaceuticals (AGIO) to Market PerformUBS Group Downgrades Agios Pharmaceuticals (AGIO) to Market Perform
www.americanbankingnews.com - February 14 at 4:54 PM
Agios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call SlidesAgios Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 14 at 3:52 PM
Agios Reports Fourth Quarter and Full Year 2017 Financial ResultsAgios Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 14 at 9:34 AM
Agios (AGIO) Q4 Loss Wider than Expected; Sales MissAgios (AGIO) Q4 Loss Wider than Expected; Sales Miss
finance.yahoo.com - February 14 at 9:34 AM
Agios Pharmaceuticals reports 4Q lossAgios Pharmaceuticals reports 4Q loss
finance.yahoo.com - February 14 at 9:34 AM
Agios Pharmaceuticals (AGIO) Announces  Earnings ResultsAgios Pharmaceuticals (AGIO) Announces Earnings Results
www.americanbankingnews.com - February 14 at 9:04 AM
Agios Pharmaceuticals (AGIO) Q4 Earnings: Whats in Store?Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
www.zacks.com - February 9 at 3:53 PM
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
finance.yahoo.com - February 9 at 3:53 PM
Agios Pharmaceuticals Inc (AGIO) Given Consensus Recommendation of "Buy" by BrokeragesAgios Pharmaceuticals Inc (AGIO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 9 at 1:04 PM
Scott Biller Sells 3,000 Shares of Agios Pharmaceuticals Inc (AGIO) StockScott Biller Sells 3,000 Shares of Agios Pharmaceuticals Inc (AGIO) Stock
www.americanbankingnews.com - February 8 at 12:46 AM
Agios Pharmaceuticals (AGIO) Scheduled to Post Earnings on WednesdayAgios Pharmaceuticals (AGIO) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 7 at 1:56 AM
Insider Selling: Agios Pharmaceuticals Inc (AGIO) Insider Sells 2,000 Shares of StockInsider Selling: Agios Pharmaceuticals Inc (AGIO) Insider Sells 2,000 Shares of Stock
www.americanbankingnews.com - February 5 at 7:02 PM
David P. Schenkein Sells 13,000 Shares of Agios Pharmaceuticals Inc (AGIO) StockDavid P. Schenkein Sells 13,000 Shares of Agios Pharmaceuticals Inc (AGIO) Stock
www.americanbankingnews.com - February 5 at 6:28 PM
Agios Pharmaceuticals Inc (AGIO) Expected to Announce Earnings of -$1.65 Per ShareAgios Pharmaceuticals Inc (AGIO) Expected to Announce Earnings of -$1.65 Per Share
www.americanbankingnews.com - February 3 at 11:04 AM
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on FebruaryAgios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February
www.nasdaq.com - February 1 at 9:31 AM
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018
finance.yahoo.com - February 1 at 9:31 AM
Agios Pharmaceuticals Inc (AGIO) CEO Sells $1,911,453.48 in StockAgios Pharmaceuticals Inc (AGIO) CEO Sells $1,911,453.48 in Stock
www.americanbankingnews.com - January 30 at 6:14 PM
Insider Selling: Agios Pharmaceuticals Inc (AGIO) Insider Sells 2,150 Shares of StockInsider Selling: Agios Pharmaceuticals Inc (AGIO) Insider Sells 2,150 Shares of Stock
www.americanbankingnews.com - January 26 at 9:44 PM
Agios Pharmaceuticals Inc (AGIO) CEO Sells $3,713,104.08 in StockAgios Pharmaceuticals Inc (AGIO) CEO Sells $3,713,104.08 in Stock
www.americanbankingnews.com - January 25 at 9:12 PM
Agios Pharmaceuticals Inc (AGIO) Insider Steven L. Hoerter Sells 25,000 SharesAgios Pharmaceuticals Inc (AGIO) Insider Steven L. Hoerter Sells 25,000 Shares
www.americanbankingnews.com - January 25 at 9:12 PM
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - GlobeNewswire (press release)Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - GlobeNewswire (press release)
globenewswire.com - January 24 at 8:05 AM
Agios Pharmaceuticals Inc (AGIO) Major Shareholder Corp /De/ Celgene Purchases 851,154 SharesAgios Pharmaceuticals Inc (AGIO) Major Shareholder Corp /De/ Celgene Purchases 851,154 Shares
www.americanbankingnews.com - January 23 at 9:32 PM
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional SharesAgios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - January 23 at 5:27 PM
UPDATE 3-Celgene to buy Juno for $9 bln to boost cancer pipelineUPDATE 3-Celgene to buy Juno for $9 bln to boost cancer pipeline
www.cnbc.com - January 22 at 3:53 PM
Agios Pharmaceuticals (AGIO) Given New $91.00 Price Target at Royal Bank of CanadaAgios Pharmaceuticals (AGIO) Given New $91.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - January 21 at 6:56 PM
Agios Pharma (AGIO) Prices 7.1M Share Common Offering at $67/ShAgios Pharma (AGIO) Prices 7.1M Share Common Offering at $67/Sh
www.streetinsider.com - January 19 at 3:27 PM
Heres Why Agios (AGIO) Stock is Up More Than 50% in a YearHere's Why Agios (AGIO) Stock is Up More Than 50% in a Year
www.zacks.com - January 19 at 3:27 PM
Here's Why Agios (AGIO) Stock is Up More Than 50% in a YearHere's Why Agios (AGIO) Stock is Up More Than 50% in a Year
finance.yahoo.com - January 19 at 3:27 PM
Agios sizes up funding needsAgios sizes up funding needs
finance.yahoo.com - January 19 at 3:27 PM
Agios Pharmaceuticals Inc (AGIO) Expected to Announce Quarterly Sales of $16.07 MillionAgios Pharmaceuticals Inc (AGIO) Expected to Announce Quarterly Sales of $16.07 Million
www.americanbankingnews.com - January 19 at 1:54 PM
Agios Announces Pricing of $475 Million Public Offering of Common StockAgios Announces Pricing of $475 Million Public Offering of Common Stock
finance.yahoo.com - January 19 at 9:13 AM
Agios Pharma (AGIO) Announces Proposed Max $400M Common Share OfferingAgios Pharma (AGIO) Announces Proposed Max $400M Common Share Offering
www.streetinsider.com - January 18 at 3:24 PM
Agios Announces Proposed Offering of Common Stock - GlobeNewswire (press release)Agios Announces Proposed Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - January 18 at 7:53 AM
Agios Announces Proposed Offering of Common StockAgios Announces Proposed Offering of Common Stock
finance.yahoo.com - January 18 at 7:53 AM
Agios Pharmaceuticals Inc (AGIO) Expected to Post Earnings of -$1.65 Per ShareAgios Pharmaceuticals Inc (AGIO) Expected to Post Earnings of -$1.65 Per Share
www.americanbankingnews.com - January 17 at 11:36 AM
Agios Pharmaceuticals Inc (AGIO) CEO Sells $3,877,480.00 in StockAgios Pharmaceuticals Inc (AGIO) CEO Sells $3,877,480.00 in Stock
www.americanbankingnews.com - January 16 at 6:36 PM
Zacks Investment Research Lowers Agios Pharmaceuticals (AGIO) to HoldZacks Investment Research Lowers Agios Pharmaceuticals (AGIO) to Hold
www.americanbankingnews.com - January 15 at 5:14 PM

SEC Filings

Agios Pharmaceuticals (NASDAQ:AGIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Agios Pharmaceuticals (NASDAQ:AGIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Agios Pharmaceuticals (NASDAQ AGIO) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.